2022-10-21

ROI-NJ: BD’s new Onclarity HPV test greatly improves standard of care for women

ROI-NJ: BD’s new Onclarity HPV test greatly improves standard of care for women

Molly Broache, Associate Director, Medical Affairs for US IDS explains how the BD Onclarity™ HPV Assay positively impacts public health by providing a more precise estimate of a woman’s risk of cervical precancer and cancer.

Latest resources

Discover our latest articles, webinars, press releases and updates in women's health.

Molly Broache, Associate Director, Medical Affairs for US IDS discusses the future of cervical cancer screening
Cervical Cancer | News & Updates
Clinical Lab Products: The Future of Cervical Cancer Screening is Here
Doctor giving patient brochure
Cervical Cancer | Articles & Publications
The Hill: What you can do to prevent cervical cancer
Chris Beddard, Vice President, U.S. Marketing, Integrated Diagnostic Solutions at BD
Cervical Cancer | News & Updates
NJBIZ Conversations: Chris Beddard